The use of monoclonal antibodies to treat Castleman's disease.

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder presenting with heterogeneous clinical features and with a complex etiology. MCD incidence is increased in people living with HIV/AIDS when it is causally associated with Kaposi's sarcoma-associated herpes virus (KSHV). HIV-seronegative individuals present with either idiopathic or KSHV-associated MCD. Central to MCD pathology is altered expression and signaling of IL-6, which promotes B-cell proliferation and causes systemic manifestations. KSHV encodes a viral homolog of human IL-6, accounting for its role in MCD, while recent evidence shows an association between IL-6 receptor polymorphisms and idiopathic MCD. The increased understanding of mechanisms underlying the pathogenesis of MCD has guided the use of new monoclonal antibody therapies for treating this complex disorder.

• Authors: Rebecca C Robey, Salvinia Mletzko, Charlotte Colley, Kirsty Balachandran, Mark Bower
• Journal: Immunotherapy (Immunotherapy) Vol. 6 Issue 2 Pg. 211-9 ( 2014) ISSN: 1750-7448 [Electronic] England
• PMID: 24491093 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Interleukin-6
• Receptors, Interleukin-6

Topics

• Antibodies, Monoclonal (therapeutic use)
• B-Lymphocytes (immunology, virology)
• Castleman Disease (epidemiology, etiology, therapy)
• Cell Proliferation
• Genetic Predisposition to Disease
• HIV Infections (epidemiology)
• Herpesviridae Infections (complications, epidemiology)
• Herpesvirus 8, Human (physiology)
• Humans
• Immunotherapy
• Interleukin-6 (metabolism)
• Polymorphism, Genetic
• Receptors, Interleukin-6 (genetics)